BCM Systems Onco-Immunology Laboratory retweeted
Multimodal spatial-omics reveal co-evolution of alveolar progenitors and proinflammatory niches in progression of lung precursor lesions dlvr.it/TQsDXl
BCM Systems Onco-Immunology Laboratory retweeted
New @NatureMedicine paper from @bcmhouston
Autologous multiantigen-targeted T cell therapy for #PancreaticCancer: a phase 1/2 trial
nature.com/articles/s41591-0…
Hard to conclude too much beyond feasibility & safety given very heterogeneous population & concurrent chemotherapy
BCM Systems Onco-Immunology Laboratory retweeted
Online Now: Spatial omics at the forefront: emerging technologies, analytical innovations, and clinical applications dlvr.it/TQ6H6c
BCM Systems Onco-Immunology Laboratory retweeted
And improvements for personalized cancer vaccines with stronger CD4+ and CD8+ responses.
cell.com/cell/fulltext/S0092…
BCM Systems Onco-Immunology Laboratory retweeted
KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer dlvr.it/TMVKGH
BCM Systems Onco-Immunology Laboratory retweeted
🫁 Tumour–microenvironment crosstalk in #NSCLC drives resistance, metastasis, and outcomes.
Understanding spatial niches, inflammation, and immune evasion can reshape treatment strategies.
📖 @NatRevClinOncol
👉 doi.org/10.1038/s41571-025-0…
#CánCare #immunotherapy #biomarkers #lcsm
BCM Systems Onco-Immunology Laboratory retweeted
This #BriefReview focuses on interferon (IFN) production in the thymus and its effects on thymic antigen presenting cells and developing thymocytes examining the importance of T-cell tolerance to IFN and interferon-stimulated proteins. Read more: ow.ly/53zc50WuPIL.
BCM Systems Onco-Immunology Laboratory retweeted
New #JITC review: Tumor organoids in immunotherapy: from disease modeling to translational research bit.ly/40ZwMGH
BCM Systems Onco-Immunology Laboratory retweeted
Today, we honor the enduring legacy of Dr. Michael E. DeBakey, a visionary surgeon, educator and medical pioneer whose groundbreaking work transformed cardiovascular surgery. Dr. DeBakey died on this day in 2008 at the age of 99, leaving behind a legacy that continues to shape modern medicine.
His innovations in surgical techniques and medical devices revolutionized heart and vascular care. His dedication to advancing medical education, research and patient care laid the foundation for generations of surgeons and continues to inspire medical professionals worldwide.
We celebrate his remarkable contributions and remain committed to carrying forward his legacy of excellence, innovation and service.
#DeBakey #BCMSurgery
Ad-SGE-DKK3 Gene Therapy Overcomes Resistance to Immune Checkpoint Blockade in Pleural Mesothelioma aacrjournals.org/clincancerr…. @CCR_AACR, @BCM_SOIL, @BCM_Surgery, @bcmhouston. #mesothelioma #Immunotherapy
1
44
BCM Systems Onco-Immunology Laboratory retweeted
🗨️ “Vaccines have done more to improve public health than any other medical intervention.”
A Viewpoint focuses on cancer vaccines and the future of immunotherapy—analysing trials, different vaccine approaches, and how the next generation of cancer vaccines can help improve patient outcomes and quality of life. hubs.li/Q03wPFhl0
BCM Systems Onco-Immunology Laboratory retweeted
This week we launched our “How To Workshop Series” with a session on understanding the grant review process, crafting specific aims, and developing a competitive research plan.
Featuring: Livia Eberlin, Ravi Ghanta, Thomas Milner, Tamer Mohamed, Hyun-Sung Lee, R. Taylor Ripley, Todd Rosengart, Hu Ying Shen, Sarah Woodfield, Ketti Eipers-Smith and Kimberly Holloway.
#NHI #MedicalResearch #HowTo #Grant #ResearchPlan
BCM Systems Onco-Immunology Laboratory retweeted
A #TopRead article from Dr. Jesse Bruijnesteijn found that a diverse repertoire of killer cell immunoglobulin-like receptors (KIRs) contributes to the protection of individuals and populations against pathogen evasion and subversion. Read it in The JI: ow.ly/vJRk50VJI7H

ALT The zinc finger arrays of different PRDM9 alleles. The zinc fingers arrays corresponding to different rhesus macaque (top) and human (bottom) PRDM9 alleles are illustrated. Each zinc finger is depicted as an oval, in which the 3 DNA contacting residues (1, 3, and 6) are provided. Different zinc fingers are indicated by distinct colors. The 2 rhesus macaque zinc fingers (SFQ, DSY) with a bold lining are also found in human PRDM9 zinc finger arrays. The frequency of each allele in the characterized rhesus macaque cohort is provided, demonstrating 2 dominant allotypes. Three alleles, PRDM9*New1, PRDM9*New8, and PRDM9*New11, encode for identical zinc finger arrays.
BCM Systems Onco-Immunology Laboratory retweeted
The innate power of NK cells in cancer therapy
@MalmbergLab @NatureMedicine
on @lab_rezvani trial
nature.com/articles/s41591-0…
BCM Systems Onco-Immunology Laboratory retweeted
TNM classification 9ᵗʰ edition
T stage
radiologyassistant.nl/chest/…
BCM Systems Onco-Immunology Laboratory retweeted
For readers interested in approaches to reset the immune system to treat autoimmune diseases, here's a comprehensive review nature.com/articles/s41573-0…
rdcu.be/elE4L
BCM Systems Onco-Immunology Laboratory retweeted
Check out the new paper by HS Lee, @BMBurtMD, @ShandaBlackmon et al about a prognosticator in pleural #mesothelioma. @BCM_Surgery @bcmhouston
Log in to #JTCVS to read this recent study from @BCMFromtheLabs on the soluble mesothelin-related peptide used as a prognosticator in pleural mesothelioma patients receiving checkpoint immunotherapy: doi.org/10.1016/j.jtcvs.2024…
BCM Systems Onco-Immunology Laboratory retweeted
New evidence today @NEJM that age-related clonal hematopoiesis (CHIP) has a driver role in evolution of solid cancers
nejm.org/doi/full/10.1056/NE…
nejm.org/doi/full/10.1056/NE…
BCM Systems Onco-Immunology Laboratory retweeted
Online now: Soluble CTLA-4 regulates immune homeostasis and promotes resolution of inflammation by suppressing type 1 but allowing type 2 immunity dlvr.it/TJsXmw
BCM Systems Onco-Immunology Laboratory retweeted
"CDK4 selective inhibition improves preclinical antitumor efficacy and safety" cell.com/cancer-cell/fulltex…
@pfizer Lars Anders
@Cancer_Cell






































